Becton, Dickinson and Company (BDX)
(Delayed Data from NYSE)
$237.17 USD
-0.29 (-0.12%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $237.10 -0.07 (-0.03%) 5:52 PM ET
3-Hold of 5 3
B Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$237.17 USD
-0.29 (-0.12%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $237.10 -0.07 (-0.03%) 5:52 PM ET
3-Hold of 5 3
B Value B Growth B Momentum B VGM
Zacks News
Becton, Dickinson Hits at a 52-Week High: What's Driving It?
by Zacks Equity Research
Becton, Dickinson (BDX) gains on solid fiscal Q3 results; view impressive.
Medtronic Unveils Inner CircleSM Program, Boosts Diabetes Arm
by Zacks Equity Research
Medtronic (MDT) focuses on initiatives to boost its diabetes business.
Becton, Dickinson Global Foothold Strong, Recalls Rampant
by Zacks Equity Research
Becton, Dickinson (BDX) gains from solid global foothold in Q3; foreign exchange headwinds raise concern.
Becton, Dickinson (BDX) Earnings and Revenues Beat in Q3
by Zacks Equity Research
Becton, Dickinson (BDX) gains from solid segmental and geographical sales in Q3.
Becton Dickinson (BDX) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 2.11% and 0.97%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Medical Product Earnings Lineup for Aug 2: ABC, BDX & More
by Zacks Equity Research
Strong R&D focus is likely to be the key driver of the Medical Product space in Q2.
Can BD Medical Drive Becton, Dickinson's (BDX) Q3 Earnings?
by Zacks Equity Research
Becton, Dickinson's (BDX) core BD Medical likely to register solid results in Q3; a possible decline in BD Life Sciences raises concern.
Stock Market News For Jul 12, 2018
by Zacks Equity Research
Wall Street closed sharply lower on Wednesday ending its four-day winning streak
Stock Market News For Jul 11, 2018
by Zacks Equity Research
U.S. stock markets continues their winning streak for the fourth straight session as all three major indexes ended up in positive territory on Tuesday
BD Buys TVA Medical, To Provide Minimally Invasive Procedure
by Zacks Equity Research
The acquisition of TVA Medical will enable Becton, Dickinson (BDX) to treat patients with chronic kidney disease through minimally invasive procedures.
Will Flagship Impella Drive Abiomed's (ABMD) Q1 Earnings?
by Zacks Equity Research
Abiomed's (ABMD) first-quarter fiscal 2019 earnings are likely to be driven by an exclusive Impella product line. Intense competition raises concern.
Can International Sales Drive Baxter's (BAX) Q2 Earnings?
by Zacks Equity Research
Baxter's (BAX) Q2 earnings likely to be aided by promising international ventures and acquisitions; cyclophosphamide competition raises concern.
Here's Why You Should Hold on to Becton, Dickinson Stock Now
by Zacks Equity Research
Becton, Dickinson (BDX) gains from strong fundamentals. Recent product recall issues raise concern.
Zacks Industry Outlook Highlights: Becton and Dickinson, Johnson & Johnson, Cigna and CVS Health
by Zacks Equity Research
Zacks Industry Outlook Highlights: Becton and Dickinson, Johnson & Johnson, Cigna and CVS Health
Medical Device Industry Outlook - June 2018
by Zacks Equity Research
The medical device industry's global annual sales is forecast to rise more than 5% a year to reach nearly $800 billion by 2030.
Why Is Becton, Dickinson (BDX) Down 2.4% Since its Last Earnings Report?
by Zacks Equity Research
Becton, Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Becton, Dickinson (BDX) Beats on Q2 Earnings & Revenues
by Zacks Equity Research
Becton, Dickinson (BDX) gains on solid segmental performance; raises fiscal 2018 guidance.
What's in Store for DENTSPLY (XRAY) This Earnings Season?
by Zacks Equity Research
DENTSPLY's (XRAY) CAD/CAM unit is likely to drive the top line in Q1. Product innovations and strong R&D prospects are also likely to drive growth.
Should You Sell Becton, Dickinson (BDX) Before Earnings?
by Zacks Equity Research
Becton, Dickinson (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP.
Cigna to Take Over Express Scripts (ESRX) for $67 Billion
by Zacks Equity Research
Per a definitive agreement, Cigna will take over Express Scripts (ESRX) in a cash-and-stock transaction worth $67 billion.
Becton, Dickinson (BDX) Down 1.3% Since Last Earnings Report
by Zacks Equity Research
Becton, Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DENTSPLY (XRAY) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Strong performance at Dental & Healthcare Consumables segment drives DENTSPLY's (XRAY) Q4 sales.
Patterson Companies (PDCO) Misses on Q3 Earnings, Cuts View
by Zacks Equity Research
Lower sales and gross-margin compression mars Patterson Companies' (PDCO) results in Q3.
Express Scripts (ESRX) Q4 Earnings Top, Long-Term View Solid
by Zacks Equity Research
Express Scripts' (ESRX) fourth-quarter 2017 results benefit from rise in patient claims and strong customer retention.
MedTech's Long-Term Prospects Outweigh Near-Term Risks
by Mark Vickery
A growing prevalence of minimally invasive surgeries, rising demand for liquid biopsy tests, use of IT for ensuring quick and improved patient care and the shift of the payment system to a value-based model are among the updates.